California pharma deals expected to decrease for the second consecutive year.
California is by a considerable margin the top state for tech deals in the US, but it faces competition for the top spot in pharma. Massachusetts could overtake it for the No. 1 rank this year. Deals in California are set to drop to 117 this year, down from 128 in 2016, marking the 2nd-consecutive down year.
Comparatively, at the current run-rate, Massachusetts and New York are projected to see slight upswings in deal count to private pharma companies in 2017. Below are the comparative deal totals for each state in 2017 year-to-date.
1. California, 60 deals
2. Massachusetts, 46 deals
3. New York, 15 deals